SAB Biotherapeutics, Inc.
SABS
$2.19
$0.13956.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -37.06M | -34.28M | -34.11M | -45.57M | -40.32M |
| Total Depreciation and Amortization | 3.31M | 3.59M | 4.79M | 4.95M | 4.97M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 757.50K | -2.19M | -2.68M | 3.25M | 2.70M |
| Change in Net Operating Assets | 2.22M | 1.54M | -2.30M | -842.00K | -4.43M |
| Cash from Operations | -30.77M | -31.34M | -34.29M | -38.21M | -37.08M |
| Capital Expenditure | -155.70K | -208.20K | -337.30K | -349.80K | -334.80K |
| Sale of Property, Plant, and Equipment | 500.00 | 500.00 | -- | 0.00 | 44.50K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.20M | 24.28M | -11.63M | -21.01M | -19.96M |
| Cash from Investing | 18.05M | 24.07M | -11.96M | -21.36M | -20.25M |
| Total Debt Issued | 516.00K | 516.00K | 516.00K | 765.20K | 765.20K |
| Total Debt Repaid | -1.27M | -1.35M | -1.42M | -1.44M | -929.80K |
| Issuance of Common Stock | 0.00 | 0.00 | 20.40K | 59.68M | 59.68M |
| Repurchase of Common Stock | -27.00K | -27.00K | -24.90K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 7.50M | 7.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -25.00K | -93.70K | -261.10K | -261.10K | -236.10K |
| Cash from Financing | -804.90K | -952.10K | -1.17M | 66.25M | 66.78M |
| Foreign Exchange rate Adjustments | -19.30K | -170.40K | -241.20K | 65.60K | 18.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.55M | -8.39M | -47.67M | 6.75M | 9.47M |